H1 results (30 November 2015) noted that the Allersys allergy system could launch in spring 2016, with 37 optimised assays out of 40 targeted for launch. Omega’s Visitect CD4 test to monitor HIV patients shows a variability related to the ambient temperature. The cause is now known and a solution is being developed; the launch date is still uncertain. An Indian production facility in Pune starts operation in FY17 and should lead to sales gains in infectious disease products. Overall H1 sales were up 8% at £6.2m. Adjusted EPS was higher at 0.6p vs 0.5p due to a £135k tax credit.
